Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure.

The New England Journal of Medicine
Milton PackerEMPEROR-Reduced Trial Investigators

Abstract

Sodium-glucose cotransporter 2 (SGLT2) inhibitors reduce the risk of hospitalization for heart failure in patients regardless of the presence or absence of diabetes. More evidence is needed regarding the effects of these drugs in patients across the broad spectrum of heart failure, including those with a markedly reduced ejection fraction. In this double-blind trial, we randomly assigned 3730 patients with class II, III, or IV heart failure and an ejection fraction of 40% or less to receive empagliflozin (10 mg once daily) or placebo, in addition to recommended therapy. The primary outcome was a composite of cardiovascular death or hospitalization for worsening heart failure. During a median of 16 months, a primary outcome event occurred in 361 of 1863 patients (19.4%) in the empagliflozin group and in 462 of 1867 patients (24.7%) in the placebo group (hazard ratio for cardiovascular death or hospitalization for heart failure, 0.75; 95% confidence interval [CI], 0.65 to 0.86; P<0.001). The effect of empagliflozin on the primary outcome was consistent in patients regardless of the presence or absence of diabetes. The total number of hospitalizations for heart failure was lower in the empagliflozin group than in the placebo group...Continue Reading

References

Jun 13, 2017·The New England Journal of Medicine·Bruce NealUNKNOWN CANVAS Program Collaborative Group
Sep 20, 2019·The New England Journal of Medicine·John J V McMurrayUNKNOWN DAPA-HF Trial Committees and Investigators
Mar 17, 2020·JACC. Heart Failure·Nasrien E IbrahimJames L Januzzi

❮ Previous
Next ❯

Citations

Sep 24, 2020·Expert Review of Cardiovascular Therapy·Marianna LeopoulouPeter Magnusson
Sep 25, 2020·Circulation·Subodh VermaMikhail N Kosiborod
Sep 1, 2020·The New England Journal of Medicine·John A Jarcho
Sep 16, 2020·Nature Reviews. Cardiology·Gregory B Lim
Sep 20, 2020·European Journal of Heart Failure·Javed ButlerMilton Packer
Oct 8, 2020·Heart Failure Reviews·Anuradha LalaUNKNOWN IDEAL-HF
Oct 20, 2020·BMC Cardiovascular Disorders·Enrique Gallego-ColonCiarán Martin Fitzpatrick
Oct 2, 2020·Diabetes, Obesity & Metabolism·Victor OkunrintemiDoyle M Cummings
Oct 22, 2020·The Journal of Clinical Hypertension·Kazuomi KarioSatoshi Hoshide
Oct 24, 2020·Cardiovascular Research·Constanze Schmidt, Sveva Bollini
Oct 24, 2020·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·Tamara Y MilderJerry R Greenfield
Oct 29, 2020·The Annals of Pharmacotherapy·Michael Gillette, Biykem Bozkurt
Nov 4, 2020·Expert Opinion on Pharmacotherapy·Emanuel RaschiFabrizio De Ponti
Nov 8, 2020·Nature Reviews. Nephrology·Usha Panchapakesan, Carol Pollock
Nov 10, 2020·Circulation. Heart Failure·Muhammad Shahzeb KhanStephen J Greene
Oct 2, 2020·European Heart Journal. Cardiovascular Pharmacotherapy·Gianluigi Savarese
Nov 18, 2020·Circulation. Heart Failure·Emil Wolsk, Finn Gustafsson
Nov 22, 2020·Diabetes Care·James A Shaw, Mark E Cooper
Nov 22, 2020·Nature Reviews. Nephrology·Radica Z AlicicKatherine R Tuttle
Nov 21, 2020·Clinical Research in Cardiology : Official Journal of the German Cardiac Society·Justas SimonavičiusHans-Peter Brunner-La Rocca
Dec 6, 2020·ESC Heart Failure·Daniela TomasoniMarco Metra
Dec 10, 2020·Nature Reviews. Endocrinology·Kamlesh Khunti
Dec 1, 2020·European Journal of Heart Failure·Milton PackerUNKNOWN EMPEROR Trial Committees and Investigators
Dec 15, 2020·Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association·Hans-Joachim AndersPaola Romagnani
Dec 1, 2020·European Journal of Heart Failure·Eva M BoorsmaAdriaan A Voors
Sep 9, 2020·Expert Review of Cardiovascular Therapy·Niki KatsikiVasilios Kotsis
Dec 8, 2020·Diabetes, Obesity & Metabolism·Giovanni Antonio SilveriiEdoardo Mannucci
Dec 30, 2020·Journal of the American Heart Association·Harvey D White
Dec 18, 2020·Expert Opinion on Investigational Drugs·Ernest A AdeghateKornelia Tekes

❮ Previous
Next ❯

Related Concepts

Related Feeds

CV Disorders & Type 2 Diabetes

This feed focuses on the association of cardiovascular diseases in patients with type 2 diabetes.

Cardiac Cachexia

Cardiac cachexia is a syndrome associated with the progressive loss of muscle and fat mass. It most commonly affects patients with heart failure and can significantly decrease the quality of life and survival in these patients. Here is the latest research on cardiac cachexia.

Cardiovascular Disorder in Diabetes

Diabetes is associated with an increased risk of cardiovascular disorders and heart failure. Discover the latest research here.

Related Papers

The New England Journal of Medicine
Stefan D AnkerEMPEROR-Preserved Trial Investigators
The New England Journal of Medicine
Sanchit Kumar, Sanjeev Sinha
The New England Journal of Medicine
Mayooran Shanmuganathan, Rohan M Goswami
The New England Journal of Medicine
Laurent FauchierDenis Angoulvant
The New England Journal of Medicine
Debdatta Bhattacharyya, Ayan Kar
© 2022 Meta ULC. All rights reserved